Nervgen Pharma Corp (NGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 62,688 | 12,070 | 15,795 | 8,249 | 11,333 |
| Marketable Securities | N/A | N/A | 6 | 24 | 42 |
| Receivables | 145 | 68 | 58 | 250 | 70 |
| Other current assets | 87 | 0 | 0 | 210 | 179 |
| TOTAL | $64,870 | $14,848 | $16,318 | $9,186 | $11,920 |
| Non-Current Assets | |||||
| Intangibles | 275 | 288 | 293 | 307 | 316 |
| TOTAL | $275 | $288 | $293 | $307 | $316 |
| Total Assets | $65,145 | $15,136 | $16,611 | $9,493 | $12,236 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,097 | 4,285 | 3,333 | 3,924 | 3,775 |
| Other current liabilities | 49,569 | 6,812 | 10,783 | 7,680 | 9,083 |
| TOTAL | $52,666 | $11,097 | $14,123 | $11,628 | $12,900 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $52,666 | $11,097 | $14,123 | $11,628 | $12,900 |
| Shareholders' Equity | |||||
| Common Shares | 108,245 | 78,643 | 73,716 | 65,682 | 63,926 |
| Retained earnings | -128,321 | -108,197 | -105,039 | -87,003 | -83,298 |
| Other shareholders' equity | 32,555 | 33,593 | 33,811 | 19,185 | 18,708 |
| TOTAL | $12,479 | $4,039 | $2,488 | $-2,135 | $-664 |
| Total Liabilities And Equity | $65,145 | $15,136 | $16,611 | $9,493 | $12,236 |